Nektar Therapeutics (NASDAQ:NKTR) traded at $24.45 at close of the session on Tuesday, June 24 and made an upward move of 156.29% on its previous day’s price.
Looking at the stock we see that its previous close was $9.54 and the beta (5Y monthly) reads 0.556 with the day’s price range being $16.56 – $27.68. In terms of its 52-week price range, NKTR has a high of $22.79 and a low of $6.48. The company’s stock has gained about 146.97% over that past 30 days.
Nektar Therapeutics has a market cap of $303.34 million and is expected to release its quarterly earnings report on 2025-May-08.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 28.12M, with a low of 25.6M and a high of 30.65M. The median projection represents growth squeezing down to 19.73% compared to sales growth for the corresponding quarter a year ago.
On the other hand, looking at the outlook for the NKTR stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of 50% Sell.
Based on estimates by 3 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Nektar Therapeutics (NKTR) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 129.37% off its SMA20 and 135.52% from its 50-day simple moving average. The RSI (14) is pointing at 81.53 while the volatility over the past week is 45.97% and jumps to 23.11% over the past one month. The average price target for the stock over the next 12 months is $18.5, with the estimates having a low of $6 and a high of $24. These price ends are 75.46% and 1.84% off the current price level respectively, although investors could be excited at the prospect of a 24.34% if the NKTR share price touches on the median price of $18.5.
Coming back to Nektar Therapeutics (NASDAQ:NKTR), we note that the average 3-month trading volume was 242.00K, while that of the preceding 10-day period stands at 4.35 million. Current shares outstanding are 12.41 million.
The insiders hold 3.59% of the company’s shares. The data shows that short shares as of 2025-05-30, stood at 0.75 million at a short ratio of 5.89. This represents a 626.00 short interest in shares outstanding on 2025-05-30. Shares short rose in May from the previous month at 0.6 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 49.54% up in year-to-date price movement.
